DiversifyRx

APRIL 29, 2025

Should You Keep Compounding GLP1s (Tirzepatide or Semaglutide) After the FDA Deadline? Howdy pharmacy peeps… Lets have a real talk about compounding GLP1s. Deadlines For Compounding GLP1s (Semaglutide & Tirzepatide) Stay up to date on the FDA’s opinion at their website HERE. Here’s My Take.

Compounding

Pharmaceutical Commerce

JULY 31, 2025

4 Meanwhile, Jim Shehan, chair of the FDA regulatory practice at Lowenstein Sandler, expressed 5 his concern to me, noting that “we do know that a very large percentage of the recent deal making has been in licensing of Chinese drugs by the global pharmaceutical industry. July 31, 2025. Accessed July 31, 2025. February 3, 2025.

Insurance

Pharmacy Times

JULY 18, 2025

Rumore, PharmD, Esq, MS, LLM, FAPhA Key Takeaways The removal of tirzepatide and semaglutide from the FDA's shortage list impacts 503A compounders, requiring adherence to complex legal and regulatory frameworks. SHOW MORE GLP-1 compounding faces legal challenges, evolving FDA rules, and heightened enforcement risks.

Compounding